These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19846165)

  • 1. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model.
    Chan ES; Patel AR; Smith AK; Klein JB; Thomas AA; Heston WD; Larchian WA
    J Urol; 2009 Dec; 182(6):2926-31. PubMed ID: 19846165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
    Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
    Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
    Liang ZK; Zhang L; Hu ZM; Chen Z; Huang X; Shi XH; Tan WL; Gao JM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):627-30. PubMed ID: 19403380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice.
    Sindhwani P; Hampton JA; Baig MM; Keck R; Selman SH
    J Urol; 2001 Oct; 166(4):1498-501. PubMed ID: 11547120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.
    Nativ O; Dalal E; Hidas G; Aronson M
    Int J Urol; 2006 Oct; 13(10):1344-6. PubMed ID: 17010016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
    Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
    Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
    Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
    Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.
    Hadaschik BA; Black PC; Sea JC; Metwalli AR; Fazli L; Dinney CP; Gleave ME; So AI
    BJU Int; 2007 Dec; 100(6):1377-84. PubMed ID: 17850390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study.
    Ibrahiem EH; Nigam VN; Brailovsky CA; Madarnas P; Elhilali M
    Cancer Res; 1983 Feb; 43(2):617-22. PubMed ID: 6848183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed.
    Khandaker MH; Kadhim SA; Ichim TE; Howson-Jan K; Chin J; Singhal SK
    Anticancer Res; 2000; 20(1A):183-9. PubMed ID: 10769653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
    Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy.
    Asanuma H; Arai T; Seguchi K; Kawauchi S; Satoh H; Kikuchi M; Murai M
    J Urol; 2003 Feb; 169(2):718-20. PubMed ID: 12544350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse orthotopic models for bladder cancer research.
    Chan E; Patel A; Heston W; Larchian W
    BJU Int; 2009 Nov; 104(9):1286-91. PubMed ID: 19388981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.
    Moltedo B; Faunes F; Haussmann D; De Ioannes P; De Ioannes AE; Puente J; Becker MI
    J Urol; 2006 Dec; 176(6 Pt 1):2690-5. PubMed ID: 17085197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GFP image analysis in the mouse orthotopic bladder cancer model.
    De Velasco MA; Tanaka M; Anai S; Tomioka A; Nishio K; Uemura H
    Oncol Rep; 2008 Sep; 20(3):543-7. PubMed ID: 18695904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo targeted contrast enhanced micro-ultrasound to measure intratumor perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model.
    Chan ES; Patel AR; Larchian WA; Heston WD
    J Urol; 2011 Jun; 185(6):2359-65. PubMed ID: 21511281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64.
    Yu DS; Lee CF; Chang SY
    J Urol; 2007 Feb; 177(2):738-42. PubMed ID: 17222673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAMLET treatment delays bladder cancer development.
    Mossberg AK; Hou Y; Svensson M; Holmqvist B; Svanborg C
    J Urol; 2010 Apr; 183(4):1590-7. PubMed ID: 20172551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
    Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
    Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.